CVS Caremark identified GLP-1 drugs and Humira as points of contention, but the State Health Plan says that mischaracterizes ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Health-care companies rose amid sales growth optimism. Drug-store chain CVS Health said it has seen complaints of strong push back from patients on its pharmacy-benefit manager's move to favor Novo ...

NEW YORK — CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1.

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk's Wegovy.

Novo Nordisk announces that CVS Caremark®, the country's largest PBM, has decided Wegovy® will be the preferred GLP-1 ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Other factors can affect access. This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...